Signal transduction and biochemical targeting of ovarian carcinoma

George Weber, F. Shen, W. Li, H. Yang, K. Y. Look, M. Abonyi, N. Prajda

Research output: Contribution to journalArticle

7 Scopus citations


The purpose was to identify novel targets for the chemotherapy of ovarian carcinoma. Methods: Assays were worked out to measure the activities of PI kinase, PIP kinase and PLC in ovarian carcinoma samples and in OVCAR-5 cells and to compare the activities to those in normal ovaries. A method was also designed for measuring the concentration of the end product of signal transduction, IP3. Results and Discussion: Signal transduction activity was markedly increased in ovarian cancer cells as shown by the increased steady-state activities of the three enzymes and the elevated concentrations of IP3. Inhibitors blocked activities of PI kinase (quercetin), PIP kinase (genistein), and lowered GTP concentration required for PLC (tiazofurin). Combinations of tiazofurin with quercetin, tiazofurin with genistein, and quercetin with genistein yielded a synergistic kill of ovarian cancer cells. Tiazofurin, quercetin and genistein are in various stages of clinical trials. Conclusion: The increased signal transduction activity provides novel, sensitive targets to chemotherapy in ovarian cancer cells.

Original languageEnglish (US)
Pages (from-to)231-236
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Issue number3
StatePublished - Aug 2 2000


  • Genistein
  • IP
  • Ovarian carcinoma
  • PI kinase
  • PIP kinase
  • PLC
  • Quercetin
  • Signal transduction
  • Tiazofurin

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Fingerprint Dive into the research topics of 'Signal transduction and biochemical targeting of ovarian carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Weber, G., Shen, F., Li, W., Yang, H., Look, K. Y., Abonyi, M., & Prajda, N. (2000). Signal transduction and biochemical targeting of ovarian carcinoma. European Journal of Gynaecological Oncology, 21(3), 231-236.